Søgning på udtrykket 'hiv' giver 154 resultater
Dokumenter [14]
Sider [7]
Kalender [86]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Dokumenter [14]
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Version: 3. Endelig guideline: 01.09.2020. Guideline skal revideres senest: 01.09.2023
Arbejdsgruppens medlemmer: Peer Brehm Christensen, Christian Erikstrup, Jan Gerstoft, Terese Katzenstein, Alex Laursen, Suzanne Lunding, Birgitte Mørn og Nina Weis.
Arbejdsgruppen bestod af: Jan Gerstoft, Ann-Brit Eg Hansen, Gitte Kronborg, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen, Niels Obel og Alex Laursen
Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.
medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering.
Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi.
Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.
Senest revideret september 2021 . Arbejdsgruppen bestod af: Jan Gerstoft, Gitte Kronborg , Ann Brit Eg Hansen, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen , Niels Obel og Alex Laursen
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Arrangeret af Yngre Infektionsmedicinere
Henvendelse til Danske regioner
I forbindelse med Sundhedsstyrelsens udgivelse af "Personer med øget risiko ved COVID-19. Fagligt grundlag", har DSI beskrevet følgende specialespecifikke patienter med øget risiko for et alvorligt COVID-19 sygdomsforløb.
Anbefaling for profylakse og opfølgning af stikuheld og anden blodeksposition.
Arbejdsgruppe: Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Sider [7]
Formål:
At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme.
Tid og sted:
Hvidovre Hospital. Lokale 10 i undervisningsbygningen.
Delkursusledere:
Ann-Brit Eg Hansen og Ole Kirk.
Program:
Mandag 3. oktober:
10:00-10:15 Velkomst og introduktion (Ann-
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
æsentanter i diverse arbejdsgrupper og udvalg, og publicerede guidelines.
Antiretroviral terapi:
Henrik Nielsen, Jan Gerstoft, Jens Lundgren, Alex Laursen, Niels Obel, Olav Larsen, Gitte Kronborg, Ann-Brit Eg Hansen
Antiviral behandling af hiv smittede personer,
Fertilitetsbehandling ved HIV og hepatitis B og C,
HIV behandling af gravide,
HIV post exposure profylakse (PEP),
Pre-exposure profylakse mod HIV (PrEP),
Borrelia:
Anne-Mette Lebech, Sigurdur Skarphedinsson
r 2021
Gastroenterologiske infektioner og kronisk hepatitis:
Dato for næste kursus
Efterår 2023:
Sted
Hvidovre Hospital
Delkursusledelse
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser
3. og 4. december 2020
HIV-infektion:
Næste kursus
Efterår 2025 (2 dage):
Sted
Afventer
Delkursusledelse
Ole Schmeltz Søgaard og Lene Ryom Nielsen
Program
Afventer
Tidligere kurser
12. og 13. oktober 2022
7. og 8. oktober 2019
3. og 4. oktober 2016
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV. De udfordringer som den vestlige verden, trods udbredt og gratis behandlingstilbud, har med at få styr på smittespredning blandt fx mænd-der-har-sex-med-mænd viser, at det - der intuitivt synes ligefor - ikke nødvendigvis virker når det kommer t
Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring.
Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler. Det har været debatteret om forskelle i antiretrovirale lægemidlers penetrans over blod/hjerne barrieren har betydning for HAND og for AIDS-definerende opportunistisk infektion i hjernen.
Der er ingen tvivl om at koncentr
Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig).
Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem.
Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud
Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den
Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling. Omkostning ifm nyttevirkning er central i at forbedre be
dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III). Dette faktum er universelt og set for praktisk tage
Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.
Kalender [86]
27. oktober 2024, Glasgow, Skotland
23. juli, Brisbane, Australien og virtuelt
1. juni, Mærsk Tårnet, Panum Instituttet, København
10. maj, Avignon, Frankrig
27. januar, Karen Brahe auditoriet, Odense Adelige Jomfrukloster (og online)
14. december 2022, Statens Institut for Folkesundhed og online
23. oktober 2022, Glasgow, Skotland
20. oktober 2022, Washington DC, USA
12. oktober 2022, Hvidovre Hospital
28. september 2022, Stockholm, Sverige
22. september 2022, Barcelona, Spanien
10. juni 2022, Panum, København
17. maj 2022, Niels K. Jerne auditoriet, Panum Instituttet, København
10. maj 2022, Avignon, Frankrig
6. december 2021, Rigshospitalet
26. november 2021, Panum, København
30. september 2021, Barcelona, Spanien
18. juli 2021, Berlin, Tyskland
28. oktober 2020, Paris, Frankrig
25. oktober 2020, Glasgow, Skotland
28. august 2020, Online og Henrik Dam auditoriet, Maersk Tårnet
10. marts 2020, KolleKolle, Værløse
7. oktober 2019, København
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
13. maj 2019, København, Odense, Aarhus
6. marts 2019, KolleKolle, Værløse
2. november 2018, Mærsk Tower, København
28. oktober 2018, Glasgow, Skotland
30. maj 2018, Rom, Italien
16. maj 2018, Marseille, Frankrig
4. maj 2018, Hindsgavl, Middelfart
28. februar 2018, Nielsine Nielsen Auditorium, Mærsk Tårnet, København
23. februar 2018, Syddansk Universitet, Odense
1. februar 2018, Nielsine Nielsen auditoriet, Mærsk Tårnet, København
6. oktober 2017, Holst Auditoriet, Mærsk tårnet, København
8. juni 2017, Hvidovre Hospital
4. maj 2017, Odense Universitetshospital
18. april 2017, Auditorium 93, Rigshospitalet
23. oktober 2016, Glasgow, Skotland
3. oktober 2016, Hvidovre Hospital
18. september 2016, Brisbane, Australien
25. maj 2016, Rom, Italien
29. april 2016, Hindsgavl, Middelfart
7. januar 2016, Medicinsk Museion, København
18. december 2015, Emil Aarestrup auditorium, Odense Universitetshospital
24. november 2015, Hvidovre Universitetshospital
8. september 2015, Panum Instituttet, København
18. juni 2015, Rigshospitalet, Teilum B
12. juni 2015, Medicinsk Museion, København
3. juni 2015, Barcelona, Spanien
24. april 2015, Auditorium 93, Rigshospitalet
17. april 2015, Foredragssalen, Statens Serum Institut
19. marts 2015, Auditorium 1, Rigshospitalet
2. november 2014, Glasgow, Skotland
5. oktober 2014, Barcelona, Spanien
5. juli 2014, Sigtuna, Sverige
18. juni 2014, Store Auditorium, Winsløwparken 15, st., 5000 Odense C
22. april 2014, Auditorium 5, Hvidovre Hospital
26. marts 2014, Barcelona, Spanien
20. februar 2014, Rigshospitalet
25. oktober 2013, Hannover auditoriet, Panum Instituttet, København
30. juni 2013, Kuala Lumpur, Malaysia
10. juni 2013, Centre for Medical Parasitology, København
3. maj 2013, Hindsgavl, Fyn
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
14. januar 2013, Auditorium 2, Rigshospitalet
10. november 2012, Auditorium 2, Rigshospitalet
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
23. oktober 2012, Rigshospitalet
2. oktober 2013, San Francisco, USA
27. september 2012, Auditorium 1, Bartholinbygningen, bygning 1241, lokale 135, Aarhus Universitet
29. februar 2012, SSI, København
9. december 2011, Rigshospitalet, københavn
7. november 2011, Auditorium 93, Rigshospitalet
13. maj 2011, Panum instituttet, København
29. april 2011, Auditorium B, Skejby
12. april 2011, Auditorium 100, Campusvej 55, 5230 Odense M, Syddansk Universitet
30. november 2007, Panum Instituttet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Background: . Kenya’s HIV epidemic is heterogeneously distributed. Although HIV incidence in Kenya has shown signs of recent decline, focused interventions are still needed for female sex workers (FSWs). Geo-spatially-informed approaches have been advocated for targeted HIV prevention. We quantified heterogeneity in HIV burden in Nairobi-based FSWs by place of origin within Kenya, and hotspots and residence within Nairobi. Methods: . Data were collected as part of enrolment in the Sex Workers Outreach P
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Background: . People with schizophrenia experience unique barriers to routine HIV testing, despite increased risk of HIV compared to the general US population. Little is known about how healthcare delivery system factors impact testing rates or whether there are testing differences for people with schizophrenia. Setting: . Nationally representative sample of Medicaid enrollees with and without schizophrenia. Methods: . Using retrospective longitudinal data, we examined whether state-level factors were as
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Background: . Sodium glucose transporter inhibitors have been approved for treatment of diabetes mellitus (DM), chronic kidney disease (CKD), and heart failure (HF), but little is known about prescription levels and safety profiles among PWH. Methods: . We leveraged data from the U.S. Mass General Brigham (MGB) electronic healthcare database to determine the use/uptake of SGLT2 inhibitors among PWH with DM2 (with or without CKD, proteinuria, or HF) and to assess rates of adverse events among PWH with DM2
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Objective: . Determine if patient-centered, streamlined HIV care achieves higher ART uptake and viral suppression than the standard treatment model for people with HIV (PWH) reporting hazardous alcohol use. Design: . Community cluster-randomized trial . Methods: . The SEARCH trial (NCT01864603) compared an intervention of annual population HIV testing, universal ART, and patient-centered care to a control of baseline population testing with ART by country standard in 32 Kenyan and Ugandan communities. Ad
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Background: . The COVID-19 pandemic led to an increase in the number of deaths among all populations, including people with diagnosed HIV (PWDH). The aim of this study was to analyze the top causes of death (COD) among PWDH prior to the start of the COVID-19 pandemic, during the start of the COVID-19 pandemic, and a year later, to determine changes in the leading COD among PWDH, as well as determine if the historical trend of decreasing deaths related to HIV continued through the pandemic. Methods: . To e
Journal of Acquired Immune Deficiency Syndromes
29.05.2023
Background: . We evaluated factors associated with lack of triple vaccination (hepatitis A (HAV), hepatitis B (HBV), human papilloma virus (HPV)] among men who have sex with men (MSM) using pre-exposure prophylaxis (PrEP). Setting: . PrEP users at San Raffaele Scientific Institute, Italy, with ≥1 follow-up visit (May 2017-2022). Methods: . Participants were considered protected if: i) prior to PrEP access: positive serology (IgG-HAV+, HbsAb>10mUI/ml) or vaccination history were recorded; ii) after star
Retrovirology
27.05.2023
Neutralizing antibodies (NAbs) protect against HIV-1 acquisition in animal models and show promise in treatment of infection. They act by binding to the viral envelope glycoprotein (Env), thereby blocking its .
Clinical Infectious Diseases
27.05.2023
AbstractBackgroundIncreased renin angiotensin aldosterone system(RAAS) activity may contribute to excess cardiovascular disease in people with HIV(PWH). We investigated how RAAS blockade may improve myocardial perfusion, injury and function among well-treated PWH.Methods40 PWH, on stable ART, without known heart disease were randomized to eplerenone 50 mg PO BID(n=20) or identical placebo(n=20) for 12 months. The primary endpoints were: 1) myocardial perfusion assessed by coronary flow reserve(CFR) on cardi
Clinical Infectious Diseases
27.05.2023
AbstractIntroductionPatients without HIV infection are increasingly recognised to be at risk for cryptococcosis. Knowledge of characteristics of cryptococcosis in these patients remains incomplete.MethodsWe conducted a retrospective study of cryptococcosis in 46 Australian and New Zealand hospitals to compare its frequency in patients with and without HIV, and describe its characteristics in patients without HIV. Patients with cryptococcosis between January 2015 and December 2019 were included.ResultsOf 475
Clinical Infectious Diseases
27.05.2023
AbstractBackgroundThe lateral flow urine lipoarabinomannan assay, Determine TB-LAM (Determine LAM), offers the potential for timely tuberculosis (TB) treatment among people living with HIV (PWH).MethodsIn this cluster-randomized trial, Determine LAM was made available with staff training with performance feedback at three hospitals in Ghana. Newly admitted PWH with a positive WHO four-symptom screen for TB, severe illness, or advanced HIV were enrolled. The primary outcome was days from enrollment to TB tre
Clinical Infectious Diseases
27.05.2023
AbstractBackgroundHistoplasmosis is a major AIDS-defining illness in Latin America. Liposomal amphotericin B (L-AmB) is the drug of choice for treatment, but access is restricted due to the high drug and hospitalization costs of the conventional long regimens.MethodsProspective randomized multicenter open-label trial of one or two-dose induction therapy with L-AmB versus control for disseminated histoplasmosis in AIDS, followed by oral itraconazole therapy. We randomized subjects to: (i) Single dose 10 mg/k
Journal of the American Medical Association
27.05.2023
Although a disproportionate number of mpox cases—between 35% and 47%, according to some studies—occur in people who also have HIV infection, research comparing the safety and outcomes of mpox treatments in patients with and without HIV is lacking.
Clinical Infectious Diseases
27.05.2023
AbstractThe World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first year. In contrast, most observational studies using routine data find same-day ART to be associated with lower engagement in care. We argue that this discrepancy is mainly driven by different time points o
PLoS One Infectious Diseases
27.05.2023
to, Nataniel Dengo, Abdul R. Cassamo, Rene Nhantumbo, Carlos Mahumane, Atanásio Mabote, Silvia Mikusova, Amâncio Nhangave, Nilesh Bhatt, Sushant S. Mukherjee . Background In Mozambique, 38.7% of women and 60.4% of men ages 15–59 years old living with HIV do not know their HIV status. A pilot home-based HIV counseling and testing program based on index cases in the community was implemented in eight districts in Gaza province (Mozambique). The pilot targeted the sexual partners, biological children unde
BMC Infectious Diseases
27.05.2023
. Abstract. . Background. The Gambian Ministry of Health is supportive of HIV self-testing (HIVST) and HIVST initiatives are being piloted as an additional strategy to increase HIV testing for individuals not currently reached by existing services, particularly men. This study aimed to determine awareness of HIVST among Gambian men, and whether prior awareness of HIVST is associated with recent HIV testing uptake. .
BMC Infectious Diseases
27.05.2023
. Abstract. . Objectives. To make clear the roles of social interaction and social support in HIV infection among elderly men who visit female sex workers (FSW). . . . Methods. We conducted a case-control study: 106 newly HIV (+) vs. 87 HIV (-) elderly men who visited FSW with similar age, education levels, marital statuses, monthly expenses
Retrovirology
26.05.2023
Several mechanisms including reduced CCR5 expression, protective HLA, viral restriction factors, broadly neutralizing antibodies, and more efficient T-cell responses, have been reported to account for HIV cont.
Journal of Infectious Diseases
26.05.2023
AbstractBackgroundThis study examined the effects of HIV on resting state functional connectivity (RSFC) in a large cohort of people living with HIV (PWH) and healthy controls without HIV (PWoH). Within PWH analyses focused on the effects of viral suppression and cognitive impairment on RSFC.MethodsA total of 316 PWH on stable combination antiretroviral therapy and 209 demographically matched PWoH were scanned at a single institution. Effects of the virus were examined by grouping PWH by detectable (viral l
Journal of Infectious Diseases
26.05.2023
AbstractBackgroundBone mineral density (BMD) loss may be accelerated in people with HIV (PLWH). It is unknown whether an individual polygenic risk score (PRS) is associated with low BMD in PLWH.MethodsWe included Swiss HIV Cohort Study participants of self-reported European descent, each with >2 per-protocol Dual X-ray Absorptiometry (DXA) measurements >2 years apart (2011-2020). We obtained uni-/multivariable odds ratios (OR) for DXA-defined osteoporosis based on traditional and HIV-related osteoporosis ri
BMC Infectious Diseases
26.05.2023
. Abstract. . Objectives. To make clear the roles of social interaction and social support in HIV infection among elderly men who visit female sex workers (FSW). . . . Methods. We conducted a case-control study: 106 newly HIV (+) vs. 87 HIV (-) elderly men who visited FSW with similar age, education levels, marital statuses, monthly expenses
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
ProMED
27.05.2023
maniasis -- BrazilIntroduction: Human visceral leishmaniasis (VL) is a zoonosis of great importance to public health due to its epidemiological diversity, with emphasis on the possibility of aggravation by coinfection with the human immunodeficiency virus (HIV).Objective: The aim was to study the epidemiological characteristics of VL cases associated with HIV coinfection in Pará. Methods. Reported cases of VL from January 2006 to December 2016 were investigated. A descriptive epidemiological method related
Medscape Infectious Diseases
19.04.2023
A test for HIV, hepatitis B, and hepatitis C that uses a single dried blood spot could increase testing for these viruses in high-risk and challenging settings, new data show. . Medscape Medical News
Medscape Infectious Diseases
18.04.2023
Fewer women are giving birth to newborns with HIV, but the success does not extend to some communities. . Medscape Medical News
Statens Serum Institut
11.04.2023
De nyeste tal fra Statens Serum Institut viser, at der ikke blev fundet nogen hiv-positive bloddonorer i bloddonorscreeningen i 2019 og kun ganske få tilfælde af hepatitis B og C.
Medscape Infectious Diseases
31.03.2023
The ruling applies nationwide, and public health experts were quick to criticize the decision. . WebMD Health News
Medscape Infectious Diseases
17.03.2023
Three quarters of US adults have never tested for HIV. Why are we still behind the 8 ball? . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
15.03.2023
This report describes the worldwide progress of eliminating HIV as a global public health threat through the use of antiretroviral therapy.
Morbidity and Mortality Weekly Report (MMWR)
10.03.2023
This report describes the identification of HIV cluster among Hispanic or Latino gay, bisexual, and other men who have sex with men in Atlanta.
Morbidity and Mortality Weekly Report (MMWR)
10.03.2023
This report describes efforts to reduce female-to-male transmission of HIV through CDC supported voluntary male circumcision programs.
Eurosurveillance latest updates
9.03.2023
. Background. Epidemiological and immunovirological features of people living with HIV (PLWH) can vary by sex. Aim. To investigate, particularly according to sex, characteristics of PLWH who consulted a tertiary hospital in Barcelona, Spain, in 1982–2020. Methods. PLWH, still in active follow-up in 2020 were retrospectively analysed by sex, age at diagnosis, age at data extraction (December 2020), birth place, CD4+ cell counts, and virological failure. Results. In total, 5,377 PLWH (compri
Medscape Infectious Diseases
23.02.2023
"It shows it's not impossible -- it's just very difficult -- to remove HIV from the body." . WebMD Health News
Morbidity and Mortality Weekly Report (MMWR)
27.01.2023
This report describes an increase in people with HIV infection receiving PEPFAR-supported antiretroviral therapy in Uganda.
Medscape Infectious Diseases
20.01.2023
"It's obviously disappointing," Anthony Fauci, MD, told MSNBC, noting that other areas of HIV treatment research are promising. "I don't think that people should give up on the field of the HIV vaccine." . WebMD Health News
Medscape Infectious Diseases
22.12.2022
Cases of late HIV might be averted if multi-prong strategies are implemented, including redefining the category for better monitoring. . Medscape Medical News
Medscape Infectious Diseases
20.12.2022
An epidemiologist and advocates say state and local officials in West Virginia, home to one of the worst HIV outbreaks in recent years, have taken measures that render syringe exchange less accessible. . Kaiser Health News
Medscape Infectious Diseases
15.12.2022
Revised draft preexposure prophylaxis recommendations highlight the need for HIV prevention in all at-risk persons while insurers consider pricing tiers. . Medscape Medical News
Medscape Infectious Diseases
6.12.2022
'At the most general level, the trial results show that one can design vaccines that induce antibodies with pre-specified genetic features, and this may herald a new era of precision vaccines.' . WebMD Health News
Statens Serum Institut
2.12.2022
I Danmark fortsætter den positive udvikling med færre nye hiv-diagnoser. Det gælder især blandt mænd der har sex med mænd (MSM), som er den gruppe, der er mest ramt af hiv. Det viser årsopgørelsen for HIV i 2021 fra Statens Serum Institut.
Morbidity and Mortality Weekly Report (MMWR)
2.12.2022
This report describes HIV services and outcomes during the COVID-19 pandemic in the United States.
Eurosurveillance latest updates
1.12.2022
. Background. Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim. To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods. Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testin